

Interfacing Chemical Biology and Drug Discovery

Confirmed Speakers

Invited Lectures

Taming Random Conjugation: A General Approach for Equimolar Linking of Proteins and Payloads



Dr Sergii KOLODYCH
(SYNDIVIA, ILLKIRCH, France)

Chemical Biology Tools for Enlightening Therapies



Prof. Olalla VÁZQUEZ
(PHILIPPS-UNIVERSITÄT MARBURG, Marburg, Germany)


Plenary Lectures

A Long Quest for DNA Methylation Inhibitors and their Use to Kill Resistant Malaria Parasites



Dr Paola ARIMONDO
(INSTITUT PASTEUR - CNRS UMR3523, Paris, France)

Multi-target-Directed Ligands to Combat Neurodegenerative Diseases: All-In-One and One-For-All



Prof. Maria Laura BOLOGNESI
(UNIVERSITY OF BOLOGNA, Bologna, Italy)

Daridorexant - A Dual Orexin Receptor Antagonist



Dr Christoph BOSS
(IDORSIA PHARMACEUTICALS LTD, Allschwil, Switzerland)

The Genetic Code in Two Dimensions



Prof. Thomas CARELL
(LUDWIG-MAXIMILIANS-UNIVERSITY, München, Germany)

Bioorthogonal Protein Activation in Living Systems



Prof. Peng CHEN
(PEKING UNIVERSITY, Beijing, China)

Nanomedicine for the Treatment of Cancer and Neurological Disorders



Prof. Patrick COUVREUR
(UNIVERSITE PARIS-SACLAY, Paris, France)

Recent Advances in Breast Cancer Treatment: Discovery of SAR439859, a Selective Estrogen Receptor Degradar for the Treatment of Estrogen-Receptor-Positive Breast Cancer.

Interfacing Chemical Biology and Drug Discovery

Confirmed Speakers



Dr Youssef EL AHMAD
(SANOFI, Vitry Sur Seine, France)

Peptide-Derived Ligands with Tailored Flexibility and their Use for Intracellular Targets



Prof. Tom GROSSMANN
(VU UNIVERSITY AMSTERDAM, Amsterdam, The Netherlands)

Ligand-directed Labeling of Endogenous Proteins in Live Cells



Prof. Itaru HAMACHI
(KYOTO UNIVERSITY, Kyoto, Japan)

Selecting Targets to Harness the Therapeutic Opportunities Afforded by PROTAC-mediated Protein Degradation



Dr John HARLING
(GLAXOSMITHKLINE, Stevenage, United Kingdom)

Expanding the Genetic Code - Chemistry in Living Systems



Prof. Kathrin LANG
(TECHNICAL UNIVERSITY OF MUNICH, Garching, Germany)

Converting Drug Delivery Technologies into Drugs in Unmet Medical Needs



Prof. Jean-Christophe LEROUX
(ETH ZÜRICH, Zürich, Switzerland)

Biomimetic Chemistry of Human RNAi Therapeutics



Dr Mano MANOHARAN
(ALNYLAM PHARMACEUTICALS, Cambridge, United States)

Drugging KRAS with Medchem 2.0



Dr Darryl MCCONNELL
(BOEHRINGER INGELHEIM RCV, Vienna, Austria)

Sulfatase Inhibitors: From Concept to Clinical Trials and Beyond



Prof. Barry POTTER
(UNIVERSITY OF OXFORD, Oxford, United Kingdom)

From Simple to Complex: Bio-inspired Strategies to Escape “Flatland”

Interfacing Chemical Biology and Drug Discovery

Confirmed Speakers



Prof. Erwan POUPON
(UNIVERSITÉ PARIS-SUD, Châtenay-Malabry, France)

Paul Ehrlich Prize 2020 Listening to Probes: Individuals and Populations



Prof. Stuart SCHREIBER
(HARVARD UNIVERSITY, Cambridge, United States)

Targeting Protein-Protein Interactions in Receptor Complexes



Prof. Kristian STROMGAARD
(UNIVERSITY OF COPENHAGEN, Copenhagen, Denmark)

Identification of the Potent, Highly Selective and Orally Bioavailable ATR Inhibitor BAY 1895344



Dr Franz VON NUSSBAUM
(BAYER AG, Berlin, Germany)